173.90Open173.90Pre Close0 Volume10 Open Interest90.00Strike Price0.00Turnover0.00%IV4.30%PremiumDec 20, 2024Expiry Date163.01Intrinsic Value100Multiplier18DDays to Expiry10.89Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.55Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet